Open Access<p>The CXCR4 Antagonist, AMD3100, Reverses Mesenchymal Stem Cell-Mediated Drug Resistance in Relapsed/Refractory Acute Lymphoblastic Leukemia</p>
Author(s) -
Shan Wang,
Xiaojiao Wang,
Sha Li,
Shengnan Zhang,
Xudong Wei,
Yongping Song,
Qingsong Yin
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s249425
Subject(s) - refractory (planetary science) , mesenchymal stem cell , medicine , lymphoblastic leukemia , antagonist , cancer research , cxcr4 , drug resistance , cxcr4 antagonist , pharmacology , drug , leukemia , oncology , pathology , biology , receptor , chemokine , astrobiology , microbiology and biotechnology
To investigate the role of the CXCR4/CXCL12 axis in chemotherapy resistance in refractory/relapsed (R/R) ALL patients.